DE69427467T2 - Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren - Google Patents

Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Info

Publication number
DE69427467T2
DE69427467T2 DE69427467T DE69427467T DE69427467T2 DE 69427467 T2 DE69427467 T2 DE 69427467T2 DE 69427467 T DE69427467 T DE 69427467T DE 69427467 T DE69427467 T DE 69427467T DE 69427467 T2 DE69427467 T2 DE 69427467T2
Authority
DE
Germany
Prior art keywords
pct
date
inclusion complexes
ranitidine
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69427467T
Other languages
English (en)
Other versions
DE69427467D1 (de
Inventor
Wilfried Fischer
Karin Klokkers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal AG filed Critical Hexal AG
Publication of DE69427467D1 publication Critical patent/DE69427467D1/de
Application granted granted Critical
Publication of DE69427467T2 publication Critical patent/DE69427467T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69427467T 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren Expired - Lifetime DE69427467T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9306024 1993-03-05
PCT/EP1994/000645 WO1994020091A1 (en) 1993-03-05 1994-03-04 Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation

Publications (2)

Publication Number Publication Date
DE69427467D1 DE69427467D1 (de) 2001-07-19
DE69427467T2 true DE69427467T2 (de) 2002-06-06

Family

ID=10984320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427467T Expired - Lifetime DE69427467T2 (de) 1993-03-05 1994-03-04 Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren

Country Status (10)

Country Link
US (1) US5665767A (de)
EP (1) EP0687174B1 (de)
JP (1) JPH09502698A (de)
AT (1) ATE201990T1 (de)
CA (1) CA2157190A1 (de)
CZ (1) CZ224995A3 (de)
DE (1) DE69427467T2 (de)
RU (1) RU2143896C1 (de)
WO (1) WO1994020091A1 (de)
ZA (1) ZA941544B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001129A1 (en) * 1994-07-06 1996-01-18 Farmarc Nederland B.V. Inclusion complexes of ranitidine
EP1367057B1 (de) * 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
RU2203048C2 (ru) * 1998-08-18 2003-04-27 Леонидов Николай Борисович Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US20040202694A1 (en) * 2003-04-11 2004-10-14 Vascular Control Systems, Inc. Embolic occlusion of uterine arteries
PT1793862E (pt) * 2004-08-02 2011-04-08 Chiesi Farma Spa Processo para a preparação de um composto de inclusão de piroxicam:beta-ciclodextrina
EP2439201B1 (de) 2006-06-16 2013-08-07 H. Lundbeck A/S Verbindungen mit kombinierter sert, 5-ht3 und 5-ht1a-aktivität
US8889243B2 (en) 2012-08-16 2014-11-18 3M Innovative Properties Company Mechanical fastening nets and methods of making the same
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity
JP2023517760A (ja) * 2020-03-19 2023-04-26 ユニバーシティ オブ ピッツバーグ - オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション シクロデキストリン複合体としての化合物の安定化

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione

Also Published As

Publication number Publication date
EP0687174A1 (de) 1995-12-20
ZA941544B (en) 1994-10-31
DE69427467D1 (de) 2001-07-19
EP0687174B1 (de) 2001-06-13
RU2143896C1 (ru) 2000-01-10
US5665767A (en) 1997-09-09
CZ224995A3 (en) 1995-12-13
CA2157190A1 (en) 1994-09-15
JPH09502698A (ja) 1997-03-18
ATE201990T1 (de) 2001-06-15
WO1994020091A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
DE69427467D1 (de) Kristallinische cyclodextrin-einschlusskomplexe von ranitidinhxdrochlorid und verfahren
YU17297A (sh) Inkluzioni kompleksi aril-heterocikličnih soli
BR0213877A (pt) Compostos orgânicos
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DE69428334D1 (de) Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
ES2243579T3 (es) Derivados de pirazolopirideno.
MEP9309A (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing the same
DE60013161D1 (de) Neue fucosylierte oligosaccharide und verfahren zu deren herstellung
AR002878A1 (es) Una formulacion liquida de 1,2-benzoisotiazolin-3-ona y un metodo para prepararla.
DE69625354D1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
BR9905089A (pt) Derivados macrolìdeos
DK0422497T3 (da) Inklusionskomplekser med Silybinin, deres fremstilling af farmaceutiske præparater, der indeholder dem
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
KR930012036A (ko) 골 흡수 억제용 약제학적 조성물
HUP0004177A2 (hu) 4,5-Diaril-oxazol származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ES2191430T3 (es) Antraciclinas 13-dihidro-3'-azaridino.
EE200200302A (et) Küllastumata 14,15-tsüklopropanoandrostaanid, nende valmistamise meetod ja neid ühendeid sisaldavadfarmatseutilised kompositsioonid
EE03284B1 (et) Pestitsiidse toimega ühendid, nende valmistamise protsess, neid sisaldavad koostised ja meetod nende kasutamiseks
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
KR920007625A (ko) 실리비닌(Silybinin)으로 구성된 포접착물, 그것의 제조방법 및 그것을 함유하는 약학적 조성물

Legal Events

Date Code Title Description
8330 Complete renunciation